PGT-M After an Uncertain Genetic Result: Why a VUS Needs Review

A genetic report can show a named variant and still leave the most important question unanswered: does it cause the condition the family fears? Couples understandably want to avoid transmitting a serious illness, but testing embryos for an uncertain finding can create misleading decisions.

PGT-M is a laboratory process designed for selected, usually well-characterised monogenic conditions. It typically requires prior testing, counselling, assay planning and coordination with an IVF laboratory. Finding a genetic difference is not the same as showing that it is pathogenic. Classifications can change as scientific evidence accumulates.

A genetics professional may review the laboratory classification criteria, relatives’ confirmed diagnoses, segregation information and whether another explanation for the illness exists. Some family members may need appropriate testing, but this should be directed by the specialist, not ordered indiscriminately. Patients should ask what the result does and does not establish.

Before creating embryos for PGT-M, obtain a clear written explanation of clinical utility, technical limitations, possibility of no interpretable result and implications for remaining embryos. Discuss the role of prenatal diagnostic choices, which may still be relevant. Do not assume PGT-M can screen every disease or eliminate all genetic risk.

HomeIVF may support initial record collection, remote genetics discussion and appropriately verified home blood collection. Embryo biopsy, genetic laboratory processing, IVF/ICSI and embryo transfer remain facility-based. Testing plans require specialist and laboratory coordination, informed consent and applicable Indian legal requirements.

HomeIVF is a doctor-led fertility-care coordination model, not a device that performs IVF at home. When verified and suitable, it may reduce avoidable journeys using teleconsultation, selected home blood collection or prescribed injection assistance. A doctor must still review results and authorise treatment changes. Ovarian imaging requires ultrasound equipment; IUI and egg retrieval require clinical facilities; sperm preparation, IVF/ICSI and embryo handling require specialised laboratories; and embryo transfer is facility-based. The precise scope of any support must be confirmed before care is planned.

Ask for separate estimates for genetics appointments, family testing, assay development where relevant, IVF procedures, embryo biopsy, genetic laboratory analysis, freezing, storage and later transfer. Clarify costs if the VUS cannot be used to design a clinically meaningful test.

A useful written estimate distinguishes required medical work from contingent and optional items. The patient should know whether a changed protocol, further imaging, embryo freezing, storage, later transfer or a second attempt alters the cost. Consent should describe meaningful risks and alternatives. The Assisted Reproductive Technology (Regulation) Act, 2021 sets a legal framework for registered ART care and written consent in India; readers should discuss its application to their treatment with the provider, rather than treating a website as legal advice.

In fertility care, timing is sometimes clinically important: a monitoring scan, a hormone sample or a prescribed medication can inform a decision within a particular window. Other tasks, including discussion of previous records or a financial estimate, are usually less time sensitive. Ask the team to separate medically fixed appointments from those that may be handled remotely. This is a safer way to reduce travel than promising a predetermined number of visits.

Genetic information is sensitive. Couples should discuss who receives the reports, whether relatives are contacted and how incidental findings will be handled. Avoid statements that a “negative embryo” guarantees a healthy child; no test provides that certainty.

If a required result is delayed, the coordinator should escalate it to the treating clinic, not improvise a medication change. Severe or rapidly worsening abdominal pain, heavy bleeding, fainting, fever, breathing difficulty or other concerning symptoms need timely professional assessment. Emergency care cannot be replaced by a chatbot, self-interpreted laboratory value or an asynchronous home-service request. Patients should have the right contact details and a suitable facility plan before treatment starts.

• What is established by these reports, and what remains uncertain?
• What additional evidence would change our plan?
• Do we need a second interpretation of imaging or laboratory findings?
• Which care steps can be discussed remotely without losing safety?
• Who is responsible if a test or appointment is delayed?
• Are add-on treatments supported by evidence for this situation?
• What is the written total-cost pathway and follow-up plan?

Ask the treating specialist to provide one written summary: the working diagnosis or uncertainty, decisions already made, the next required test or visit, who interprets it and the alternatives if results change. Carry forward original records rather than ordering every test again. Request an itemised estimate before payment and confirm the next appointment directly with the appropriate licensed provider. These simple steps make it easier for a second clinician to understand the case if a referral becomes necessary.